Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis

被引：28

作者：

Hayat, Sawsan J.

Uppal, Sukhbir S. ^{[1
]}

Nampoory, M. R. Narayanan

Johny, Kaivilayil V.

Gupta, Ramkumar

Al-Oun, Mohammed

机构：

[1] Kuwait Univ, Fac Med, Dept Med, Kuwait, Kuwait

[2] Kuwait Univ, Dept Med, Kuwait, Kuwait

[3] Mubarak Al Kabeer Hosp, Kuwait, Kuwait

来源：

CLINICAL RHEUMATOLOGY | 2007年 / 26卷 / 06期

关键词：

D O I：

10.1007/s10067-006-0219-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Because disease activity in systemic lupus erythematosus correlates well with increased serum levels and activity of the cytokine tumor necrosis factor alpha (TNF-alpha), we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNF-alpha, given to a patient with active lupus with diffuse proliferative nephritis (WHO Class IV). This patient who failed to remit with a combination of full-dose steroids, mycophenolate mofetil, and cyclosporine, went into sustained remission with the addition of infliximab infusions.

引用

页码：973 / 975

页数：3

共 14 条

[1]

Aten J, 2000, J AM SOC NEPHROL, V11, P1426, DOI 10.1681/ASN.V1181426

[2]

Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO

[3]

2-D

[4] Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease acitivity in systemic lupus erythematosus [J].

Davas, EM ;

Tsirogianni, A ;

Kappou, I ;

Karamitsos, D ;

Economidou, I ;

Dantis, PC .

CLINICAL RHEUMATOLOGY, 1999, 18 (01) :17-22

[5]

Gilboe IM, 2001, J RHEUMATOL, V28, P266

[6]

Hellmann D B, 1991, Md Med J, V40, P923

[7]

Louis M, 2003, J RHEUMATOL, V30, P2557

[8]

Pisetsky DS, 2000, ARTHRITIS RHEUM, V43, P2381, DOI 10.1002/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO

[9]

2-M

[10]

PROKOPYEV AA, 1993, TERAPEVT ARKH, V65, P9

← 1 2 →